Open Label Excerpt: We still have to rely heavily on post-marketing safety surveillance systems to alert us to type B (unpredictable) adverse reactions because open-label extension studies are unlikely to provide useful information about these types of often serious and relatively rare adverse reactions

Read More: https://investorshangout.com/post/newpost/605...z6hevfovzG

LL has been in type B study for years. We are ahead of the game. GLTA.